Lantern Pharma Reports Q2 2025 Results, LP-184 Phase 1a Trial Complete.

• Lantern Pharma completes LP-184 Phase 1a trial with 65 patient enrollments. • LP-184 has market potential of $10-12 billion USD in annual revenue. • Maximum tolerated dose and recommended Phase 2 dose established for LP-184. • LP-184 Phase 1b/2 trials planned for recurrent TNBC and bladder cancer. • Complete response observed in HARMONIC Trial patient with advanced NSCLC.

Lantern Pharma Inc. (NASDAQ: LTRN) has achieved a significant milestone in its clinical pipeline with the successful completion of the Phase 1a trial for LP-184. The trial enrolled 65 patients across various solid tumor indications, including glioblastoma (GBM), triple negative breast cancer (TNBC), and others. This marks a pivotal step forward for Lantern Pharma, as LP-184 has shown promising results and holds substantial market potential [1].

The Phase 1a trial established both the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for LP-184, positioning it for advancement to Phase 1b/2 studies. These trials are planned for recurrent TNBC and recurrent bladder cancer, two indications with large market potential. The company has received Fast Track Designations from the FDA for GBM and TNBC, along with four Rare Pediatric Disease Designations for specific pediatric cancers [1].

LP-184 is a next-generation acylfulvene drug candidate, designed to preferentially damage DNA in cancer cells overexpressing specific biomarkers or harboring mutations in DNA damage repair pathways. It is a prodrug that is activated inside the cancer cell by PTGR1, an enzyme overexpressed in certain cancers, leading to irreparable DNA damage and tumor cell death. The drug candidate is the product of years of research and leverages Lantern Pharma's proprietary AI platform, RADR®, which utilizes over 200 billion oncology-focused data points [1].

In addition to the Phase 1a trial, Lantern Pharma has observed remarkable clinical activity in a Phase 2 trial (HARMONIC™). A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) demonstrated a complete response in target cancer lesions following treatment with LP-300 in combination with chemotherapy. This outcome builds on previous data showing an 86% clinical benefit rate and 43% objective response rate in the initial safety lead-in cohort [1].

Lantern Pharma's stock price and market capitalization have shown resilience in recent quarters, reflecting investor confidence in the company's pipeline and technological advancements. The company's disciplined capital management, with approximately $15.9 million in cash, cash equivalents, and marketable securities as of June 30, 2025, provides an expected operating runway through at least June 2026 [1].

References:
[1] https://finance.yahoo.com/news/lantern-pharma-reports-second-quarter-203000443.html